Optimind Pharma Past Earnings Performance
Past criteria checks 0/6
Optimind Pharma's earnings have been declining at an average annual rate of -12%, while the Healthcare industry saw earnings growing at 0.3% annually. Revenues have been declining at an average rate of 9.7% per year.
Key information
-12.0%
Earnings growth rate
8.5%
EPS growth rate
| Healthcare Industry Growth | -6.7% |
| Revenue growth rate | -9.7% |
| Return on equity | -2,334.9% |
| Net Margin | -1,939.1% |
| Last Earnings Update | 30 Nov 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Optimind Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Nov 23 | 0 | -3 | 1 | 0 |
| 31 Aug 23 | 0 | -3 | 1 | 0 |
| 31 May 23 | 0 | -3 | 1 | 0 |
| 28 Feb 23 | 0 | -3 | 1 | 0 |
| 28 Feb 22 | 0 | 0 | 0 | 0 |
Quality Earnings: OMND is currently unprofitable.
Growing Profit Margin: OMND is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if OMND's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare OMND's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OMND is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (6.7%).
Return on Equity
High ROE: OMND has a negative Return on Equity (-2334.92%), as it is currently unprofitable.